Nivelreuma - Käypä hoito suosituksen tiivistelmä

TamPub

Kuvailutiedot

dc.contributor.author Hakala, Markku -
dc.contributor.author Hannonen, Pekka -
dc.contributor.author Helve, Tapani -
dc.contributor.author Korpela, Markku -
dc.contributor.author Mattila, Kimmo -
dc.contributor.author Möttönen, Timo -
dc.contributor.author Varis, Tiina -
dc.date.accessioned 2012-06-17T20:15:10Z
dc.date.available 2012-06-17 03:57:47 -
dc.date.available 2012-06-17T20:15:10Z
dc.date.issued 2009 -
dc.identifier.issn 0012-7183 -
dc.identifier.uri http://tampub.uta.fi/handle/10024/66054
dc.description.abstract English summary: Rheumatoid arthritis (updated Current Care guideline) Anti-citrulline antibodies are highly specific to rheumatoid arthritis (RA) and are thus helpful in differential diagnosis. Early and aggressive disease modifying anti-rheumatic drug (DMARD) therapy is essential for a positive treatment result in cases of RA. Remission during the 1st year of treatment predicts permanent remission, milder joint damage and better functional ability. It is recommended that patients with an unsatisfactory response to DMARDs, including methotrexate and a combination of DMARDs, should be treated primarily with TNF blockers, and non-responders with rituximab or abatacept. RA is an independent risk factor for cardiovascular diseases. The assessment of cardiovascular risk must not be forgotten in daily practice.   -
dc.language.iso fi -
dc.title Nivelreuma - Käypä hoito suosituksen tiivistelmä -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-803 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Sisätaudit | en=Internal Medicine| -
dc.journal.title Duodecim -
dc.journal.volume 125 -
dc.journal.number 19 -
dc.journal.volumepagerange 2131-2132 -
dc.oldstats 48 -

Viite kuuluu kokoelmiin:

Kuvailutiedot